Veracyte's CEO talks about ESMO data from its prostate cancer diagnostic that could change how metastatic prostate cancer is treated

blonca9
Sep 16, 2024
1 min read

Marc Stapley explains how the company's Decipher Prostate Test, already successful commercially in localized prostate cancer, could help determine whether chemotherapy is appropriate on top of androgen deprivation therapy for metastatic patients.

Recent Posts

See All

CLAIRITY BREAST, an AI platform that predicts five-year breast cancer risk from routine mammograms, became the first such AI tool to receive FDA authorization for breast cancer prediction

Cullinan Therapeutics' CEO Nadim Ahmed covers last week's #ASCO25 data for zipalertinib in EGFRex20 insertion lung cancer, plus an in-depth conversation about bispecifics for autoimmune conditions

AI News: Artera presented data at #ASCO25 showing that its AI platform can identify prostate cancer patients most likely to benefit (or not benefit) from added androgen receptor inhibitor therapy

Veracyte's CEO talks about ESMO data from its prostate cancer diagnostic that could change how metastatic prostate cancer is treated

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight